MARS: A sense of perspective and an inconvenient truth

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages

  Treasure, Tom ^a   Utley, Martin ^a   O'Byrne, Ken ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); EXTERNAL VALIDITY; EXTRAPLEURAL PNEUMONECTOMY; FEASIBILITY STUDY; HUMAN; LETTER; LUNG RESECTION; MULTIMODALITY CANCER THERAPY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84876380971     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318286c72b     Document Type: Letter

References (5)

1. Treasure T, Lang-Lazdunski L, Waller D, et al.; MARS trialists. Extra-pleural pneumonec-tomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothe-lioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-772.
2. Kindler HL. Robust data: the essential foundation of a revised staging system for pleural meso-thelioma. J Thorac Oncol 2012;7:1623-1624.
3. Rusch V W, Giroux D, Kennedy C, et al.; IASLC Staging Committee. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012;7:1631-1639.
4. Treasure T, Waller D, Tan C, et al. The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study. J Thorac Oncol 2009;4:1254-1258.
5. Van Schil PE, Baas P, Gaafar R, et al.; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-1369.